CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Krystal Biotech, Inc. - KRYS CFD

103.36
0.33%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.33
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026346 %
Charges from full value of position ($-5.01)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026346%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.004124 %
Charges from full value of position ($0.78)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004124%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Krystal Biotech Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 103.8
Open* 104.45
1-Year Change* 38.05%
Day's Range* 102.89 - 105.08
52 wk Range 69.81-132.68
Average Volume (10 days) 376.62K
Average Volume (3 months) 6.54M
Market Cap 2.86B
P/E Ratio -100.00K
Shares Outstanding 28.21M
Revenue 8.56M
EPS -1.46
Dividend (Yield %) N/A
Beta 0.83
Next Earnings Date Feb 26, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 5, 2023 103.80 0.92 0.89% 102.88 104.96 101.38
Dec 4, 2023 104.68 -0.44 -0.42% 105.12 106.22 103.51
Dec 1, 2023 106.04 1.93 1.85% 104.11 106.13 101.06
Nov 30, 2023 104.15 3.72 3.70% 100.43 105.74 100.43
Nov 29, 2023 100.25 0.31 0.31% 99.94 103.08 99.93
Nov 28, 2023 100.81 1.67 1.68% 99.14 101.43 98.13
Nov 27, 2023 100.50 -1.95 -1.90% 102.45 103.38 99.59
Nov 24, 2023 102.38 0.43 0.42% 101.95 103.74 101.50
Nov 22, 2023 101.88 0.70 0.69% 101.18 102.91 100.15
Nov 21, 2023 101.17 -1.72 -1.67% 102.89 104.18 99.93
Nov 20, 2023 104.71 -1.01 -0.96% 105.72 107.04 103.93
Nov 17, 2023 104.09 6.21 6.34% 97.88 104.14 96.73
Nov 16, 2023 98.18 -1.31 -1.32% 99.49 99.79 96.66
Nov 15, 2023 99.49 -1.45 -1.44% 100.94 103.53 98.93
Nov 14, 2023 102.71 1.11 1.09% 101.60 104.98 101.60
Nov 13, 2023 99.57 4.89 5.16% 94.68 100.32 94.68
Nov 10, 2023 98.47 2.67 2.79% 95.80 98.92 93.63
Nov 9, 2023 95.88 -5.69 -5.60% 101.57 101.60 95.73
Nov 8, 2023 102.17 -6.00 -5.55% 108.17 108.17 101.44
Nov 7, 2023 108.96 5.20 5.01% 103.76 109.46 103.43

Krystal Biotech, Inc. Events

Time (UTC) Country Event
Monday, February 26, 2024

Time (UTC)

13:30

Country

US

Event

Q4 2023 Krystal Biotech Inc Earnings Release
Q4 2023 Krystal Biotech Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Revenue
Total Operating Expense 145.196 68.275 32.999 22.081 11.916
Selling/General/Admin. Expenses, Total 77.735 40.391 15.063 6.465 4.155
Research & Development 42.461 27.884 17.936 15.616 7.761
Operating Income -145.196 -68.275 -32.999 -22.081 -11.916
Interest Income (Expense), Net Non-Operating 5.221 -1.295 0.832 2.993 1.027
Net Income Before Taxes -139.975 -69.57 -32.167 -19.088 -10.889
Net Income After Taxes -139.975 -69.57 -32.167 -19.088 -10.889
Net Income Before Extra. Items -139.975 -69.57 -32.167 -19.088 -10.889
Net Income -139.975 -69.57 -32.167 -19.088 -10.889
Income Available to Common Excl. Extra. Items -139.975 -69.57 -32.167 -19.088 -10.889
Income Available to Common Incl. Extra. Items -139.975 -69.57 -32.167 -19.088 -10.889
Dilution Adjustment
Diluted Net Income -139.975 -69.57 -32.167 -19.088 -10.889
Diluted Weighted Average Shares 25.4917 22.1968 18.7872 15.9011 11.2031
Diluted EPS Excluding Extraordinary Items -5.491 -3.13423 -1.71218 -1.20042 -0.97196
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -4.51029 -3.13423 -1.71218 -1.20042 -0.97196
Total Extraordinary Items 0
Total Adjustments to Net Income 0
Unusual Expense (Income) 25
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 38.048 48.823 34.771 31.451 28.753
Selling/General/Admin. Expenses, Total 25.904 24.035 24.03 19.935 17.863
Research & Development 12.144 12.288 10.741 11.516 10.89
Operating Income -38.048 -48.823 -34.771 -31.451 -28.753
Interest Income (Expense), Net Non-Operating 4.838 3.526 2.719 1.601 0.645
Net Income Before Taxes -33.21 -45.297 -32.052 -29.85 -28.108
Net Income After Taxes -33.21 -45.297 -32.052 -29.85 -28.108
Net Income Before Extra. Items -33.21 -45.297 -32.052 -29.85 -28.108
Net Income -33.21 -45.297 -32.052 -29.85 -28.108
Income Available to Common Excl. Extra. Items -33.21 -45.297 -32.052 -29.85 -28.108
Income Available to Common Incl. Extra. Items -33.21 -45.297 -32.052 -29.85 -28.108
Diluted Net Income -33.21 -45.297 -32.052 -29.85 -28.108
Diluted Weighted Average Shares 26.6569 25.7122 25.6826 25.6191 25.5452
Diluted EPS Excluding Extraordinary Items -1.24583 -1.76169 -1.248 -1.16515 -1.10033
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -1.24583 -1.27554 -1.248 -1.16515 -1.10033
Unusual Expense (Income) 0 12.5 0 0 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 383.779 442.267 275.058 195.88 112.65
Cash and Short Term Investments 379.171 438.096 271.262 193.685 111.761
Cash & Equivalents 161.9 341.246 268.269 187.514 103.67
Prepaid Expenses 4.608 4.171 3.796 2.195 0.889
Other Current Assets, Total
Total Assets 558.45 626.295 310.844 209.023 116.116
Property/Plant/Equipment, Total - Net 169.726 119.583 34.174 11.184 3.014
Property/Plant/Equipment, Total - Gross 176.519 123.797 36.542 12.034 3.18
Accumulated Depreciation, Total -6.793 -4.214 -2.368 -0.85 -0.166
Total Current Liabilities 28.847 25.736 15.452 3.327 2.596
Accounts Payable 3.981 8.398 2.105 0.724 0.888
Accrued Expenses 24.556 17.168 5.681 2.544 1.515
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases
Total Liabilities 36.219 32.719 18.76 6.109 2.89
Total Long Term Debt 0 0 0 0 0
Long Term Debt
Other Liabilities, Total 7.372 6.983 3.308 2.782 0.294
Total Equity 522.231 593.576 292.084 202.914 113.226
Redeemable Preferred Stock 0 0
Common Stock 0.00026 0.003 0.0002 0.00017 0
Additional Paid-In Capital 803.718 734.523 363.292 241.951 133.183
Retained Earnings (Accumulated Deficit) -280.759 -140.787 -71.214 -39.047 -19.959
Total Liabilities & Shareholders’ Equity 558.45 626.295 310.844 209.023 116.116
Total Common Shares Outstanding 25.7637 25.208 19.7142 17.3543 14.4289
Other Current Liabilities, Total 0.31 0.17 7.666 0.059 0.193
Short Term Investments 217.271 96.85 2.993 6.171 8.091
Other Long Term Assets, Total 0.324 0.074 1.612 1.462 0.452
Other Equity, Total -0.72826 -0.163 0.0058 0.00983 0.002
Long Term Investments 4.621 64.371 0 0.497
Preferred Stock - Non Redeemable, Net 0 0
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 582.128 484.004 355.429 383.779 397.578
Cash and Short Term Investments 562.069 477.517 350.387 379.171 394.42
Cash & Equivalents 373.241 275.875 140.745 161.9 186.409
Short Term Investments 188.828 201.642 209.642 217.271 208.011
Prepaid Expenses 5.465 6.487 5.042 4.608 3.158
Total Assets 790.35 684.026 531.847 558.45 576.379
Property/Plant/Equipment, Total - Net 171.389 171.327 170.887 169.726 166.039
Property/Plant/Equipment, Total - Gross 182.128 180.471 178.773 176.519 171.84
Accumulated Depreciation, Total -10.739 -9.144 -7.886 -6.793 -5.801
Other Long Term Assets, Total 0.285 0.285 0.402 0.324 0.205
Total Current Liabilities 27.583 23.898 35.076 28.847 28.032
Accounts Payable 4.34 4.446 4.109 3.981 5.761
Accrued Expenses 20.776 18.778 30.595 24.556 21.681
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 2.467 0.674 0.372 0.31 0.59
Total Liabilities 34.402 30.912 42.281 36.219 35.607
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 6.819 7.014 7.205 7.372 7.575
Total Equity 755.948 653.114 489.566 522.231 540.772
Preferred Stock - Non Redeemable, Net 0
Common Stock 0.00028 0.00028 0.00026 0.00026 0.00026
Additional Paid-In Capital 1034.85 1012.62 815.776 803.718 790.954
Retained Earnings (Accumulated Deficit) -278.519 -359.266 -326.056 -280.759 -248.707
Other Equity, Total -0.38228 -0.23628 -0.15426 -0.72826 -1.47526
Total Liabilities & Shareholders’ Equity 790.35 684.026 531.847 558.45 576.379
Total Common Shares Outstanding 28.1947 27.9749 25.7962 25.7637 25.7097
Long Term Investments 36.548 28.41 5.129 4.621 12.557
Total Receivables, Net 9.316
Accounts Receivable - Trade, Net 9.316
Total Inventory 5.278
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -139.975 -69.57 -32.167 -19.088 -10.889
Cash From Operating Activities -100.569 -47.938 -26.083 -18.69 -9.445
Cash From Operating Activities 4.055 2.769 1.851 1.09 0.141
Non-Cash Items 32.54 16.811 3.305 1.306 0.792
Cash Taxes Paid
Cash Interest Paid
Changes in Working Capital 2.811 2.052 0.928 -1.998 0.511
Cash From Investing Activities -114.083 -226.77 -11.181 -4.991 -10.323
Capital Expenditures -52.979 -68.336 -14.843 -6.399 -2.234
Cash From Financing Activities 35.347 347.685 118.019 107.525 73.847
Issuance (Retirement) of Stock, Net 35.996 355.645 118.019 107.525 73.847
Issuance (Retirement) of Debt, Net 0
Net Change in Cash -179.346 72.977 80.755 83.844 54.079
Other Investing Cash Flow Items, Total -61.104 -158.434 3.662 1.408 -8.089
Financing Cash Flow Items -0.649 -7.96
Foreign Exchange Effects -0.041
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -45.297 -139.975 -107.923 -78.073 -49.965
Cash From Operating Activities -26.156 -100.569 -78.24 -58.552 -15.493
Cash From Operating Activities 0.705 4.055 2.966 1.991 1.015
Non-Cash Items 9.832 32.54 23.476 14.453 6.295
Changes in Working Capital 8.604 2.811 3.241 3.077 27.162
Cash From Investing Activities 3.563 -114.083 -108.875 -94.132 -55.908
Capital Expenditures -5.381 -52.979 -47.762 -33.706 -17.191
Other Investing Cash Flow Items, Total 8.944 -61.104 -61.113 -60.426 -38.717
Cash From Financing Activities 1.474 35.347 32.278 30.158 -0.542
Financing Cash Flow Items -0.749 -0.649 -0.649 -0.649 -0.649
Issuance (Retirement) of Stock, Net 2.223 35.996 32.927 30.807 0.107
Net Change in Cash -21.155 -179.346 -154.837 -122.526 -71.943
Foreign Exchange Effects -0.036 -0.041
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Redmile Group, LLC Investment Advisor/Hedge Fund 9.1686 2566661 653381 2023-06-30 LOW
Avoro Capital Advisors LLC Investment Advisor/Hedge Fund 9.1477 2560811 810811 2023-06-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 8.9378 2502059 -111213 2023-06-30 LOW
Krishnan (Krish S) Individual Investor 6.106 1709338 -25000 2023-09-11 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 6.0818 1702554 503610 2023-06-30 LOW
Krishnan (Suma M) Individual Investor 6.0341 1689206 -25000 2023-09-11 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 5.1634 1445463 -5791 2023-06-30 LOW
Frazier Healthcare Partners Venture Capital 3.5374 990260 44853 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 3.2281 903691 -122704 2023-06-30 LOW
Lord, Abbett & Co. LLC Investment Advisor 3.0101 842648 -118594 2023-06-30 MED
Point72 Asset Management, L.P. Hedge Fund 1.9978 559261 56861 2023-06-30 HIGH
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 1.7382 486597 24507 2023-06-30 LOW
Credit Suisse Funds AG Investment Advisor/Hedge Fund 1.6604 464818 -168001 2023-06-30 LOW
Hood River Capital Management LLC Investment Advisor 1.6163 452456 5063 2023-06-30 MED
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.587 444260 13689 2023-06-30 LOW
Pictet Asset Management Ltd. Investment Advisor/Hedge Fund 1.534 429428 -202965 2023-06-30 LOW
Nicholas Investment Partners, L.P. Investment Advisor/Hedge Fund 1.3394 374951 233 2023-06-30 MED
Invus Public Equities Advisors, LLC Investment Advisor 1.2491 349669 -62413 2023-06-30 MED
T. Rowe Price Associates, Inc. Investment Advisor 1.1221 314110 300652 2023-06-30 LOW
SEB Investment Management AB Investment Advisor 1.0211 285860 -158 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Krystal Biotech, Inc. Company profile

About Krystal Biotech Inc

Krystal Biotech, Inc. is a clinical stage biotechnology company focused on redosable gene delivery for the treatment of serious rare diseases. Using its platform that is based on engineered herpes simplex virus type 1 (HSV-1), the Company create vectors that deliver therapeutic transgenes to cells of interest in multiple organ systems. The Company’s gene therapy product candidates and undertaking preclinical studies and clinical trials of B-VEC, KB105, KB301, KB104, KB407 and KB408. The Company's KB104 is to treat Netherton Syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders associated with thickened scaly skin and characterized by chronic skin inflammation, itchiness, and dehydration.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Krystal Biotech Inc revenues was not reported. Net loss increased from $32.2M to $69.6M. Higher net loss reflects General and Administrative - Balancing increase from $12.8M to $30.2M (expense), Stock-based Compensation in SGA increase from $2.3M to $10.2M (expense), Research and Development - Balancing increase of 44% to $24.5M (expense).

Industry: Bio Therapeutic Drugs

2100 Wharton St Ste 701
PITTSBURGH
PENNSYLVANIA 15203
US

Income Statement

  • Annual
  • Quarterly

News

December RBA preview: no move expected at the final meeting of 2023

The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

14:47, 4 December 2023

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023

People also watch

XRP/USD

0.64 Price
+1.460% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

US100

15,856.20 Price
-0.080% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 22:00 (UTC)
Spread 1.8

BTC/USD

44,119.40 Price
+0.200% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Gold

2,030.07 Price
+0.480% 1D Chg, %
Long position overnight fee -0.0196%
Short position overnight fee 0.0114%
Overnight fee time 22:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading